Correlation between immunohistochemical staining and clinicopathological findings in endometrial carcinoma

References

1. 1.↵
   American Cancer Society. Cancer Facts and Figures. [Updated 2021; accessed 2024 May 15]. Available from: https://www.cancer.org/cancer/types/endometrial-cancer/about/key-statistics.html
2. 2.↵
   Saudi Health Council. Cancer incidence report: Saudi Arabia. [Updated 2020; 2023 Nov 15]. Available from: https://shc.gov.sa/Arabic/NCC/Activities/AnnualReports/Cancer%20Incidence%20Report%202020.pdf
3. 3.↵
   1. Moch H

   . Female genital tumours: WHO classification of tumours, volume 4. [Updated 2020; accessed 2023 Nov 15]. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Female-Genital-Tumours-2020
4. 4.↵
   1. Bell DW,
   2. Ellenson LH

   . Molecular genetics of endometrial carcinoma. Annu Rev Pathol 2019; 14: 339–367.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Tabata J,
   2. Takenaka M,
   3. Okamoto A

   . Molecular typing guiding treatment and prognosis of endometrial cancer. Gynecology and Obstetrics Clinical Medicine 2023; 3: 7–17.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Doghri R,
   2. Houcine Y,
   3. Boujelbène N,
   4. Driss M,
   5. Charfi L,
   6. Abbes I, et al.

   Mismatch repair deficiency in endometrial cancer: immunohistochemistry staining and clinical implications. Appl Immunohistochem Mol Morphol 2019; 27: 678–682.

   OpenUrlCrossRef
7. 7.↵
   1. Marei HE,
   2. Althani A,
   3. Afifi N,
   4. Hasan A,
   5. Caceci T,
   6. Pozzoli G, et al.

   p53 signaling in cancer progression and therapy. Cancer Cell Int 2021; 21: 703.

   OpenUrlCrossRef
8. 8.↵
   1. Köbel M,
   2. Ronnett BM,
   3. Singh N,
   4. Soslow RA,
   5. Gilks CB,
   6. McCluggage WG

   . Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility. Int J Gynecol Pathol 2019; 38 Suppl 1: S123–S131.

   OpenUrl
9. 9.↵
   1. Favier A,
   2. Varinot J,
   3. Uzan C,
   4. Duval A,
   5. Brocheriou I,
   6. Canlorbe G

   . The role of immunohistochemistry markers in endometrial cancer with mismatch repair deficiency: a systematic review. Cancers (Basel) 2022; 14: 3783.

   OpenUrl
10. 10.↵
    1. de Freitas D,
    2. Aguiar FN,
    3. Anton C,
    4. de Almeida DC,
    5. Bacchi CE,
    6. Carvalho JP, et al.

    Clinicopathological characteristics of endometrial carcinomas according to DNA mismatch repair protein status. Heliyon 2023; 9: e17495.

    OpenUrl
11. 11.↵
    1. Bounous VE,
    2. Ferrero A,
    3. Campisi P,
    4. Fuso L,
    5. Pezua Sanjinez JOS,
    6. Manassero S, et al.

    Immunohistochemical markers and TILs evaluation for endometrial carcinoma. J Clin Med 2022; 11: 5678.

    OpenUrl
12. 12.↵
    1. Kaur J,
    2. Suri A,
    3. Kaur M

    . A clinicopathological study: expression of ER, PR, and HER/2neu in endometrial carcinoma. J Obstet Gynaecol Res 2022; 5: 41–53.

    OpenUrl
13. 13.↵
    1. Serin G,
    2. Savaş P,
    3. Özdemir N,
    4. Zekioglu O,
    5. Akman L

    . Investigation of the relationship between immunohistochemical mismatch repair (MMR) protein expression and prognostic parameters in endometrial carcinomas. Adv Obstet Gynaecol Res 2023; 1: 24–31.

    OpenUrl
14. 14.↵
    1. Pasanen A,
    2. Loukovaara M,
    3. Kaikkonen E,
    4. Olkinuora A,
    5. Pylvänäinen K,
    6. Alhopuro P, et al.

    Testing for Lynch syndrome in endometrial carcinoma: from universal to age-selective MLH1 methylation analysis. Cancers (Basel) 2022; 14: 1348.

    OpenUrl
15. 15.↵
    1. Pasanen A,
    2. Loukovaara M,
    3. Bützow R

    . Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma. Mod Pathol 2020; 33: 1443–1452.

    OpenUrl
16. 16.↵
    1. Momeni-Boroujeni A,
    2. Dahoud W,
    3. Vanderbilt CM,
    4. Chiang S,
    5. Murali R,
    6. Rios-Doria EV, et al.

    Clinicopathologic and genomic analysis of TP53-mutated endometrial carcinomas. Clin Cancer Res 2021; 27: 2613–2623.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Bogani G,
    2. Ray-Coquard I,
    3. Concin N,
    4. Ngoi NYL,
    5. Morice P,
    6. Caruso G, et al.

    Endometrial carcinosarcoma. Int J Gynecol Cancer 2023; 33: 147–174..

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Tresa A,
    2. Sambasivan S,
    3. Rema P,
    4. Dinesh D,
    5. Sivaranjith J,
    6. Nair SP, et al.

    Clinical profile and survival outcome of endometrial cancer with p53 mutation. Indian J Surg Oncol 2022; 13: 580–586.

    OpenUrl
19. 19.↵
    1. Brett MA,
    2. Atenafu EG,
    3. Singh N,
    4. Ghatage P,
    5. Clarke BA,
    6. Nelson GS, et al.

    Equivalent survival of p53 mutated endometrial endometrioid carcinoma grade 3 and endometrial serous carcinoma. Int J Gynecol Pathol 2021; 40: 116–123.

    OpenUrlCrossRefPubMed